A new drug could bring the end of Alzheimer’s as we know it. The drug, Aducanumab is now being tested in hospitals across Great Britain. It acts as a pre-emptive strike against the cause of the disease. Initial trials of the drug have produced incredible results that are unprecedented in the health industry. If the drug continues to be effective, it could put an end to any fears of developing Alzheimer’s at a later stage in life. The disease would essentially be cured!

How Does The Drug Work?

Aducanumab targets amyloid in the brain. This is the protein that clogs the system and is the cause of Alzheimer’s. By killing off cells in the brain, it can affect speech, memory and motor control. The drug is injected before symptoms begin to develop in the hope that it will eradicate the amyloid.

There is no other drug like it on the market. Although there have been numerous studies and tests into Alzheimer’s, none of them have shown promising results. Millions have been poured into research and very little has come of it. This could be the breakthrough that scientists have hoped for. One British doctor described the drug as the best advance in medicine he has seen in his career.

Due to the way the drug works, it could put an end to Alzheimer’s before it develops. It is unclear what, if any effect, it could have on patients who are already in the later stages.

The Study

Preliminary trials tested 165 people who were experiencing the early stages of Alzheimer’s. Aducanumab was given to participants on a monthly basis. A high dosage of the drug was injected into the brains of both men and women. Within a year, the amyloid had disappeared. The results were incredible, and it will be fascinating to see whether they can be replicated.

The Results

There is no doubt that the drug shows promise. Not only did it reduce the amyloid, but it also stopped the symptoms of the disease. People with Alzheimer’s suffer from memory loss and the decline of basic functioning. Many are bedridden and need constant care or attention. A large number of individuals with Alzheimer’s end up in care facilities and need constant supervision. It affects over eight hundred thousand people across the UK.

However, it is important to realize that the drug does not necessarily mean there is now a cure for the disease. The study was too small to reach this conclusion. A larger study is now underway, and the trial will officially finish in 2020. As such we still have a few more years before we know for certain whether this disease has been beaten.

That said, it is clear that the scientific community is finally making headway against the disease. What this means, in the long run, is still uncertain. But for the first time in a while, the future for Alzheimer’s patients is starting to look a lot brighter. We can only hope that this is the sign the fight against Alzheimer’s is nearing its end.